Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives

被引:76
作者
Eldehna, Wagdy M. [1 ]
Abou-Seri, Sahar M. [2 ,3 ]
El Kerdawy, Ahmed M. [2 ,3 ]
Ayyad, Rezk R. [4 ,5 ]
Hamdy, Abdallah M. [6 ]
Ghabbour, Hazem A. [7 ]
Ali, Mamdouh M. [8 ]
Abou El Ella, Dalal A. [9 ]
机构
[1] Egyptian Russian Univ, Dept Pharmaceut Chem, Fac Pharm, POB 11829, Cairo, Egypt
[2] Cairo Univ, Dept Pharmaceut Chem, Fac Pharm, Kasr El Aini St,POB 11562, Cairo, Egypt
[3] Cairo Univ, Mol Modeling Unit, Fac Pharm, Kasr El Aini St,POB 11562, Cairo, Egypt
[4] Al Azhar Univ, Dept Pharmaceut Chem, Fac Pharm, Cairo, Egypt
[5] Delta Univ Sci & Technol, Dept Pharmaceut Chem, Fac Pharm, Mansoura, Egypt
[6] Egyptian Russian Univ, Dept Analyt Chem, Fac Pharm, POB 11829, Cairo, Egypt
[7] King Saud Univ, Dept Pharmaceut Chem, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia
[8] Natl Res Ctr, Div Genet Engn & Biotechnol, Dept Biochem, Giza 12622, Egypt
[9] Ain Shams Univ, Fac Pharm, Dept Pharmaceut Chem, POB 11566, Cairo, Abbassia, Egypt
基金
美国国家卫生研究院;
关键词
Phthalazine; VEGFR-2; Hydrophobic interaction; PHASE-II TRIAL; IN-VITRO; DISCOVERY; POTENT; ANGIOGENESIS; VATALANIB; CANCER; ANTAGONISTS; RESISTANT; UREAS;
D O I
10.1016/j.ejmech.2016.02.029
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of anilinophthalazine derivatives 4a-j was initially synthesized and tested for its VEGFR-2 inhibitory activity where it showed promising activity (IC50 = 0.636-5.76 mu M). Molecular docking studies guidance was used to improve the binding affinity for series 4a-j towards VEGFR-2 active site. This improvement was achieved by increasing the hydrophobic interaction with the hydrophobic back pocket of the VEGFR-2 active site lined with the hydrophobic side chains of Ile888, Leu889, Ile892, Val898, Val899, Leu1019 and Ile1044. Increasing the hydrophobic interaction was accomplished by extending the anilinophthalazine scaffold with a substituted phenyl moiety through an uriedo linker which should give this extension the flexibility required to accommodate itself deeply into the hydrophobic back pocket. As planned, the designed uriedo-anilinophthalazines 7a-i showed superior binding affinity than their anilinophthalazine parents (IC50 = 0.083-0.473 mu M). In particular, compounds 7g-i showed IC50 of 0.086, 0.083 and 0.086 mu M, respectively, which are better than that of the reference drug sorafenib (IC50 = 0.09 mu M). (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:50 / 62
页数:13
相关论文
共 38 条
[1]   New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis [J].
Bold, G ;
Altmann, KH ;
Frei, J ;
Lang, M ;
Manley, PW ;
Traxler, P ;
Wietfeld, B ;
Brüggen, J ;
Buchdunger, E ;
Cozens, R ;
Ferrari, S ;
Furet, P ;
Hofmann, F ;
Martiny-Baron, G ;
Mestan, J ;
Rösel, J ;
Sills, M ;
Stover, D ;
Acemoglu, F ;
Boss, E ;
Emmenegger, R ;
Lässer, L ;
Masso, E ;
Roth, R ;
Schlachter, C ;
Vetterli, W ;
Wyss, D ;
Wood, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (12) :2310-2323
[2]  
Bold G., 1998, EP Patent, Patent No. [98, 98(1998)00764]
[3]  
Boyd M.R., 2014, CANC DRUG DISCOVERY, P41
[4]   SOME PRACTICAL CONSIDERATIONS AND APPLICATIONS OF THE NATIONAL-CANCER-INSTITUTE IN-VITRO ANTICANCER DRUG DISCOVERY SCREEN [J].
BOYD, MR ;
PAULI, KD .
DRUG DEVELOPMENT RESEARCH, 1995, 34 (02) :91-109
[5]   Mechanisms of angiogenesis and arteriogenesis [J].
Carmeliet, P .
NATURE MEDICINE, 2000, 6 (04) :389-395
[6]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[7]   Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase Inhibitor [J].
Cee, Victor J. ;
Schenkel, Laurie B. ;
Hodous, Brian L. ;
Deak, Holly L. ;
Nguyen, Hanh N. ;
Olivieri, Philip R. ;
Romero, Karina ;
Bak, Annette ;
Be, Xuhai ;
Bellon, Steve ;
Bush, Tammy L. ;
Cheng, Alan C. ;
Chung, Grace ;
Coats, Steve ;
Eden, Patrick M. ;
Hanestad, Kelly ;
Gallant, Paul L. ;
Gu, Yan ;
Huang, Xin ;
Kendall, Richard L. ;
Lin, Min-Hwa Jasmine ;
Morrison, Michael J. ;
Patel, Vinod F. ;
Radinsky, Robert ;
Rose, Paul E. ;
Ross, Sandra ;
Sun, Ji-Rong ;
Tang, Jin ;
Zhao, Huilin ;
Payton, Marc ;
Geuns-Meyer, Stephanie D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (17) :6368-6377
[8]  
Dewhirst Mark W., 2008, P27
[9]   Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) [J].
Dragovich, T. ;
Laheru, D. ;
Dayyani, F. ;
Bolejack, V. ;
Smith, L. ;
Seng, J. ;
Burris, H. ;
Rosen, P. ;
Hidalgo, M. ;
Ritch, P. ;
Baker, A. F. ;
Raghunand, N. ;
Crowley, J. ;
Von Hoff, D. D. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) :379-387
[10]   VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures [J].
Dumas, J ;
Dixon, JA .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (06) :647-658